학술논문
Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors
Document Type
Article
Author
Source
In Annals of Oncology October 2020 31(10):1405-1412
Subject
Language
ISSN
0923-7534